Shares of MiNK Therapeutics, Inc. (INKT) surged on Tuesday morning after the company announced a new collaboration to develop a targeted cell therapy for pediatric cancers.
The stock is currently trading at $14.23, up $3.78 or 36.14%, on the Nasdaq. It opened at $15.71 after closing the previous session at $10.45. The stock has traded between $6.34 and $76.00 over the past 52 weeks.
MiNK Therapeutics said it has entered a strategic collaboration with C-Further, an international pediatric oncology therapeutics consortium, to develop a PRAME-targeted TCR-engineered invariant natural killer T (iNKT) cell therapy for pediatric cancers.
Under the agreement, the program could receive about $1.1 million in non-dilutive funding to support IND-enabling development, along with the potential for double-digit downstream commercial revenue participation.
The therapy will target PRAME, a tumor-associated antigen commonly expressed across several pediatric and adult cancers, including sarcomas, acute myeloid leukemia, and medulloblastoma. The program aims to advance a lead candidate toward first-in-human clinical studies in children.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.